Disruption of sncRNA Improves the Protective Efficacy of Outer Membrane Vesicles against Helicobacter pylori Infection in a Mouse Model

Li, Biaoxian; Xu, Yilian; Xu, Tian; Guo, Zhicheng; Xu, Qianwen; Li, Yang; Ling, Zeng; Huang, Xiaotian; Liu, Qiong

doi:10.1128/iai.00267-22

Cited by 11 publications

(4 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-12 and IL-4 are critical cytokines in the Th1 and Th2 cellular immune responses, respectively [ 11 ]. The IL-12 and IL-4 levels were also significantly higher in all OMV-immunized groups presenting the UreB antigen than in the control group, indicating that OMV immunization triggered both Th1 and Th2 cellular immune responses in mice, consistent with previous results ( Figures 4b, f, c, g ).…”

Section: Resultsmentioning

confidence: 99%

Outer membrane vesicles from genetically engineered Salmonella enterica serovar Typhimurium presenting Helicobacter pylori antigens UreB and CagA induce protection against Helicobacter pylori infection in mice

Liu,

Shang,

Shen

et al. 2024

Virulence

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Outer membrane vesicles from genetically engineered Salmonella enterica serovar Typhimurium presenting Helicobacter pylori antigens UreB and CagA induce protection against Helicobacter pylori infection in mice

Liu,

Shang,

Shen

et al. 2024

Virulence

Self Cite

View full text Add to dashboard Cite

“…Recent studies have shown how genetic manipulations can be easily performed with the aim to further improve OMV safety, immunogenicity, and protective efficiency. For example, it has been shown that disruption of small noncoding RNA improves the protective efficacy of OMVs against Helicobacter pylori infection in a mouse model [ 72 ]. Both intranasal and intraperitoneal immunization with flagellin-deficient S. typhimurium OMVs resulted in efficient protection against heterologous S. choleraesuis and S. enteritidis challenge [ 73 ] and immunization with OMVs from major outer membrane protein-deficient S. typhimurium mutants enhanced cross-protection [ 74 ].…”

Section: Trends Emerging In Preclinical Studiesmentioning

confidence: 99%

Outer Membrane Vesicle Vaccine Platforms

Micoli,

Adamo,

Nakakana

2023

BioDrugs

View full text Add to dashboard Cite

Outer membrane vesicles (OMVs) are spontaneously released by many gram-negative bacteria during their growth and constitute an important virulence factor for bacteria, helping them to survive through harsh environmental conditions. Native OMVs, naturally-released from bacteria, are produced at a level too low for vaccine manufacturing, requiring chemical treatment (detergent-extracted) or genetic manipulation, resulting in generalized modules for membrane antigens (GMMAs). Over the years, the nature and properties of OMVs have made them a viable platform for vaccine development. There are a few licensed OMV vaccines mainly for the prevention of meningitis caused by Neisseria meningitidis serogroup B (MenB) and Haemophilus influenzae type b (Hib). There are several candidates in clinical development against other gram-negative organisms from which the OMVs are derived, but also against heterologous targets in which the OMVs are used as carriers (e.g. coronavirus disease 2019 [COVID-19]). The use of OMVs for targets other than those from which they are derived is a major advancement in OMV technology, improving its versatility by being able to deliver protein or polysaccharide antigens. Other advances include the range of genetic modifications that can be made to improve their safety, reduce reactogenicity, and increase immunogenicity and protective efficacy. However, significant challenges remain, such as identification of general tools for high-content surface expression of heterologous proteins on the OMV surface. Here, we outline the progress of OMV vaccines to date, particularly discussing licensed OMV-based vaccines and candidates in clinical development. Recent trends in preclinical research are described, mainly focused on genetic manipulation and chemical conjugation for the use of OMVs as carriers for heterologous protein and polysaccharide antigens. Remaining challenges with the use of OMVs and directions for future research are also discussed.

show abstract

“…Antibody levels in mouse blood samples and vaginal secretions were quantified using quantitative ELISA as described previously 41 . OMP (1 mg) suspended in 100 mL of sodium carbonate buffer (pH 9.6) was used to coat each well of a 96-well plate (Nalge Nunc Inc., Naperville, IL, USA) that was incubated overnight at 4 °C.…”

Section: Elisamentioning

confidence: 99%

Recombinant outer membrane vesicles coupled with cytokines act as high-performance adjuvants againstHelicobacter pyloriinfection in mice

Liu

Lü

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

The widespread prevalence of Helicobacter pylori (H. pylori) infection remains a great challenge to the human health. The existing vaccines are not ideal for preventing H. pylori infection; thus, exploring highly effective adjuvants may improve the immunoprotective efficacy of H. pylori vaccines. In a previous study, we found that outer membrane vesicles (OMVs), a type of nanoscale particle spontaneously produced by Gram-negative bacteria, could act as adjuvants to boost the immune response to vaccine antigens. In the present study, we explored the potential application of OMVs as delivery vectors for adjuvant development. We constructed recombinant OMVs containing cytokines interleukin 17A or interferon-γ and evaluated their function as adjuvants in combination with inactivated whole-cell vaccine (WCV) or UreB as vaccine antigens. Our results showed that recombinant OMVs as adjuvants could induce stronger humoral and mucosal immune responses in mice than wild-type H. pylori OMVs and the cholera toxin (CT) adjuvant. Additionally, the recombinant OMVs significantly promoted Th1/Th2/Th17-type immune responses. Furthermore, the recombinant OMV adjuvant induced more potent clearance of H. pylori than CT and wild-type OMVs. Our data suggest that the recombinant OMVs coupled with cytokines may become potent adjuvants for development of novel and effective vaccines against H. pylori infection.

show abstract

Disruption of sncRNA Improves the Protective Efficacy of Outer Membrane Vesicles against Helicobacter pylori Infection in a Mouse Model

Cited by 11 publications

References 47 publications

Outer membrane vesicles from genetically engineered Salmonella enterica serovar Typhimurium presenting Helicobacter pylori antigens UreB and CagA induce protection against Helicobacter pylori infection in mice

Outer membrane vesicles from genetically engineered Salmonella enterica serovar Typhimurium presenting Helicobacter pylori antigens UreB and CagA induce protection against Helicobacter pylori infection in mice

Outer Membrane Vesicle Vaccine Platforms

Recombinant outer membrane vesicles coupled with cytokines act as high-performance adjuvants againstHelicobacter pyloriinfection in mice

Contact Info

Product

Resources

About